



## New doctoral thesis on ProstaLunds CoreTherm®

At the Department of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, doctoral student Fredrik Stenmark's thesis "Transurethral microwave thermotherapy and transurethral resection of the prostate" was published today. The overall aim has been, among other things, to evaluate and develop ProstaLund's method "the CoreTherm Concept". Fredrik Stenmark will defend his doctoral thesis on 21 May.

On the university's website <https://www.gu.se/forskning/fredrik-stenmark-mikrovagsterapi-en-framgangsrik-snabb-behandling-vidgodartad-prostataforstoring>, Dr Fredrik Stenmark gives an opinion on what his research can lead to in the future under the heading "Microwave therapy – a successful rapid treatment for benign prostate enlargement":

"The studies included in my dissertation have provided a basis for simplified treatment with microwaves. The results also show that large prostate glands can be treated with microwave therapy, with excellent results in the long term. Only about 10 percent of patients needed to be re-treated with surgery, the average follow-up time was 10 years."

"The research results mean that microwave therapy, which is carried out in local anesthesia for about 10 minutes even on the largest prostate glands, can now be recommended, thereby avoiding risky operations. Microwave therapy can therefore be performed regardless of the size of the prostate gland and is also suitable for patients with other diseases and blood thinner medication. The method also means that you can help patients who would otherwise not be curable, as in many cases surgeries carry excessive risks."

"It is also the case that my perspective as operations manager means that I believe that TUMT should be able to be offered more patients, as it saves surgical resources, which also improves for other patient groups. Not least important as we can, hopefully soon, start caring for all patients who are in line after the pandemic."

"Fredrik Stenmark's important research clearly shows that CoreTherm should be a fundamental cornerstone in the care of benign prostate enlargement. Both from a medical and economic perspective, our method meets a great need.", says acting CEO, Johan Wennerholm, in a comment.

**For further information, please contact:**

---

Johan Wennerholm, Acting CEO  
Tel. +46 (0) 730 429997  
Email: [johan.wennerholm@prostalund.com](mailto:johan.wennerholm@prostalund.com)



PRESS RELEASE  
03 May 2021 15:40:00 CEST

## About ProstaLund

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

### **Certified Adviser:**

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

## Attachments

---

New doctoral thesis on ProstaLunds CoreTherm®